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The Spacehaler@ . 1s a new, compact, pressurized aerosol device that uses the same canister as a 
conventional metered-dose inhaler (MDI). Its design, however, reduces the velocity of the aerosol cloud 
that emerges from the inhaler, thereby reducing the amount of the non-respirable fraction of the drug 
delivered to the patient. Large volume spacers achieve a similar effect, but they are bulky and therefore 
inconvenient to use and carry around. This study compared the bronchodilator effect of 2OOpg 
salbutamol delivered by the Spacehale@ to that of an MD1 used with a Volumatic@ spacer (MD1 plus 
spacer) in patients with reversible obstructive airways disease. 
Twenty-five patients with asthma, having a forced expiratory volume in 1 s (FEV1) between 50 and 
90% predicted and a reversibility of 2 15% to 2OOpg salbutamol given by the conventional (standard) 
MD1 entered the study. On two separate study days, they inhaled 2OOpg salbutamol either via the 
Spacehale@ or the MD1 plus spacer. To maintain blinding, they received placebo on both study days via 
the alternate device. Their FEV,, forced vital capacity (FVC) and peak expiratory flow (PEF) were 
measured before and at regular intervals for 6 h after inhalation. Assessment of equivalence between the 
two devices was based on whether the 90% confidence interval for the difference between the weighted 
mean FEV, was within f 0.25 1. Patient preference was assessed by a questionnaire at the end of the 
second study day. 
Twenty-four patients completed the study. Both devices produced a significant improvement in FEV, 
(PcO.02). The upper and lower 90% confidence limits for the difference in weighted mean FEV, between 
the devices was & 0.04 1, and the 99% confidence limits were + 0.061 and - 0.07 1. The weighted means 
for FVC and PEF, and the duration of effect and peak responses for FEV,, FVC and PEF also showed 
no difference between the two devices. Patients found no difficulty in using the Spacehaler@, and 20 out 
of 24 patients (83.3O/o) preferred it to the MD1 plus spacer. 
The bronchodilator effect of 200 pug salbutamol administered by a Spacehaler@ was equivalent to that 
produced by an MDI plus spacer in this group of patients with reversible airways obstruction. The 
majority of patients preferred it to a large volume spacer. 
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Introduction treatment of patients with reversible obstructive 
The pressurized metered-dose inhaler (MDI) is 
the most common inhaler device used for the 
airways disease, and has been available for more 
than 30 yr. It is inexpensive, reliable and efficient 
(l), and delivers multiple reproducible doses of 
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drug. However, the aerosol of drug emitted from 
the MD1 contains a large proportion of non- 
respirable particles greater than 5,~rn in diam- 
eter (2). The high velocity of the aerosol particles 
(30 m s - ‘) results in most of these impacting in 
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PLATE 1. The Spacehaler@ device (right) and the 
standard MD1 plus Volumatic@ spacer (left), to 
show relative sizes. 
the oropharynx, where up to 80% of the drug 
delivered may be deposited (3). The high velocity 
may also produce an unwanted ‘cold-Freon 
effect’, causing some patients to stop inspiration 
with the release of aerosol into the mouth (4). 
Large volume spacer devices reduce oropha- 
ryngeal deposition and the ‘cold-Freon effect’ 
(5). Spacers are of particular value in the treat- 
ment of patients requiring high-dose inhaled 
corticosteroids and patients who are prone to 
develop candidiasis with inhaled steroids (6). 
A variety of ,spacer devices are available for 
use with the standard MDI. The size of many of 
these devices, however, makes them inconven- 
ient to carry for use outside the home. A smaller 
inhalation device with a deposition profile simi- 
lar to that of a spacer which produces a slow- 
velocity spray, would be a useful alternative for 
inhaled drug therapy for patients unable to use 
the standard MD1 because of the ‘cold-Freon’ 
effect, and also for those patients using large 
volume spacers for inhaled corticosteroid 
therapy. Although dry powder inhalers may be 
appropriate for many patients, they are rela- 
tively expensive and do not reduce oropharyn- 
geal deposition. 
The Spacehale@ (previously called the 
Gentlehaler@) has been developed to address 
this requirement (7). The key benefits of the 
Spacehaler@ are: (i) that it slows down the 
velocity of the delivered dose from 30 to 2 m s - ’ 
(8); and (ii) that it retains within the device the 
majority of the non-respirable fraction of the 
emitted dose, thereby reducing oropharyngeal 
deposition (8). 
The present study compared the bronchodila- 
tor effect of 2OOpg salbutamol administered 
either via a Spacehaler@ or standard MD1 used 
in conjunction with a Volumatic@ spacer 
device (MD1 plus spacer) in patients with 
reversible obstructive airways disease. The dose 
of 2OOpg of salbutamol was chosen since this is 
the most commonly recommended dose in clini- 
cal practice. The ease of use, patient preference, 
the effects on heart rate and blood pressure and 
the occurrence of adverse events were also 
assessed. 
Methods 
SPACEHALER@ DEVICE 
The Spacehaler@ (Evans Medical Ltd, 
Leatherhead, U.K.) is a compact, low-velocity, 
pressurized aerosol device which is 7.5 cm 
long compared to the standard MD1 plus 
Volumatic@ spacer which is 26 cm long 
(Plate 1). It uses the same canister as a conven- 
tional MDI. Its design incorporates a vortex 
chamber immediately upstream of the nozzle, 
together with a narrow air inlet in the rear and a 
bell-shaped internal surface in the mouthpiece. 
The overall effect is to reduce the velocity of the 
spray and to retain most of the non-respirable 
particles within the actuator. Oropharyngeal 
deposition is therefore reduced (8). 
PATIENTS 
Twenty-five patients (13 males) with a docu- 
mented history of stable asthma entered the 
study (mean age 46 years; age range 22-70). 
There were 10 non-smokers, 11 ex-smokers and 
four current smokers. They had a forced expira- 
tory volume in 1 s (FEV1) 2 50% but 190% of 
that predicted by the European Community for 
Coal and Steel (ECCS) formulae; mean FEV, 
2.08 1 (SD 0.62 1, range 1.04-3.34 1). All showed 
an increase in FEV, of 2 15% after inhalation of 
2OOpg salbutamol using a standard MD1 (with- 
out spacer). Patients were permitted to continue 
inhaled corticosteroids, sodium cromoglycate 
and nedocromil sodium during the study, pro- 
vided that the dose was regular and remained 
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constant. Oral corticosteroids and theophyllines 
were not allowed; anti-cholinergics and oral and 
long-acting p2 agonists were discontinued for 
24 h, and short-acting p2 agonists were discon- 
tinued for 10 h prior to study visits. 
STUDY DESIGN 
This was a single-centre, randomized, double- 
blind, double-dummy, crossover study. Patients 
attended the clinic on three occasions. At the 
first visit, eligibility and reversibility criteria were 
assessed. Patients who satisfied the entry criteria 
were randomized sequentially to study treatment 
according to a computer-generated randomiz- 
ation code, and attended on two further study 
days. 
At these visits, patients received two puffs of 
salbutamol from a pressurized aerosol canister 
(100 pg puff - ‘) with one of the inhaler devices, 
and two puffs of placebo with the other inhaler 
device. One of the inhaler devices was the 
Spacehaler@ and the other was a standard MD1 
attached to a Volumatic@ spacer (Allen & 
Hanbury Ltd, Uxbridge, Middlesex, U.K.). 
Before use, each spacer was washed with warm 
soapy water and allowed to air dry overnight, to 
reduce the possibility of electrostatic attraction 
of drug particles to the spacer (9). Before inha- 
lation, the devices were primed by firing the 
Spacehaler@ or the MD1 twice into a plastic 
bag. The salbutamol and the placebo aerosol 
canisters were manufactured by Baker-Norton, 
Harlow, Essex, U.K. The device containing the 
active drug and the order of use of the devices 
were randomized in blocks of four. Lung func- 
tion measurements [FEV,, forced vital capacity 
(FVC) and peak expiratory flow (PEF)], pulse 
and blood pressure were measured before and at 
15, 30, 60, 120, 180, 240, 300 and 360 min after 
treatment. At the third visit, the baseline FEV, 
was required to be within f 15% of the value 
recorded at the second visit, so that baseline 
FEV, on both treatment days was comparable. 
All lung functions were measured using three 
factory-calibrated Microlab 3000 electronic 
turbine spirometers (Micro Medical Ltd, 
Rochester, Kent, U.K.). The calibrations were 
checked daily throughout the study to ensure 
that there was no drift. Any one patient used the 
same spirometer throughout the study. 
Approval for the study was obtained from the 
Research Ethics Committee of East Berkshire 
Health Authority. 
EVALUATION OF DEVICE HANDLING 
At the first visit, patients were given time to read 
the instructions for using the Spacehaler@ and 
the MD1 plus spacer, after which their ability to 
use the devices was assessed. The number of 
attempts required to assemble each device and 
inhale correctly was recorded. Further instruc- 
tion was given if needed, and the need for this 
was recorded. At the end of the study, patients’ 
evaluation of the ease of use of the two inhaler 
devices and their personal preference were 
assessed by a questionnaire that investigated 
previous inhaler experience, features of the study 
devices and relative convenience, portability, 
comfort and co-ordination. 
STATISTICS 
Assessment of equivalence between the two 
devices was based on the null hypothesis that 
there is a difference, and whether the 90% confi- 
dence interval for the difference between the 
weighted mean FEV, was within f 0.25 1 (lo- 
12). A sample size of 24 patients was required to 
give 90% power to detect no difference between 
treatments (10) assuming a within-patient stan- 
dard deviation of 0.25 1. Weighted mean FEV, 
was calculated by dividing the area under the 
response time curve by time. Weighted means 
were also compared for FVC and PEF, and peak 
observed values, time to onset of effect and 
duration of action were compared for FEV,, 
FVC and PEF. Onset of action was identified by 
the time point at which the test parameter 
increased by 15% or more over the baseline 
value. The duration of action was the total time 
the test parameter stayed above 15%. SAS ver- 
sion 6.08 (SAS Institute Inc., Cary, NC, U.S.A.) 
was used for the statistical procedures. Appro- 
priate parametric (ANOVA, paired t-test) and 
non-parametric (Wilcoxon rank sum test, 
Kruskall-Wallis test, survival analysis) proce- 
dures were used, taking into consideration the 
distribution and censoring of data. For all stat- 
istical tests, a significance level of 5% was used. 
All tests were two-sided. 
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FIG. 1. Change in levels of FEV, during the active 
phase of the study period. x , Spacehale@); 0, 
metered-dose inhaler plus Volumatic@ spacer. 
Results 
Of the 25 patients who entered the study, 24 
completed both study periods. One patient 
withdraw because of family bereavement. Figure 
1 shows the mean changes in FEV, ( f 2 SEM) 
from baseline to each time point up to 360 min 
(6 h). The weighted change in mean FEV, from 
baseline was 0.28 1 (SD 0.18 1) for the 
Spacehale@ and 0.27 1 (SD 0.16 1) for the MD1 
plus spacer. The adjusted mean (n=24) for 
weighted mean FEV, was 2.38 1 for the 
Spacehaler@ and 2.38 1 for the MD1 plus spacer 
device. There was no significant difference 
between the two estimated population means 
(P=O*87; 90% confidence limits, - O-043, 0.039; 
99% confidence limits, - 0.066, O-062). Individ- 
ual patient data is shown in Fig. 2. 
Multifactor ANOVA showed no difference 
between the two devices with respect to weighted 
mean FEV,. There was no effect due to period or 
the order of usage of the devices. The effect for 
patients was significant (P=O*OOOl), which was 
not unexpected due to the natural variation of 
FEV, between patients. 
The 90% upper and lower confidence limits for 
the difference between the two devices with 
respect to weighted mean FEV, were - O-043 
and O-039. The 90% confidence interval was thus 
entirely contained within the equivalence inter- 
val of f 0.25 1, and demonstrated that the two 
devices were equivalent. The 99% confidence 
4.5 
4 
3.5 
3 
s 
2.5 
E 2 
1.5 
1 
0.5 
0 
(a) (b) 
Pre Post Pre Post 
Individual baseline and post-treatment values 
FIG. 2. Individual baseline and post-treatment val- 
ues. (a) Spacehaler @, (b) metered-dose inhaler plus 
Volumatic@ spacer. 
limits ( - 0.066, O-062) were also well within the 
equivalence interval. 
There was no difference between the two 
devices for the weighted means for FVC and 
PEF and peak values, time of onset and duration 
of effect as assessed by FEV,, FVC and PEF. 
FEV, improved by an average of 0.49 1 (nz2.5, 
SEM 0.05) with the Spacehale@ and O-52 1 
(n = 24, SEM 0.02) with the MD1 plus spacer. 
These changes in FEV, were significant com- 
pared to the baseline values (P=O*Ol for the 
Spacehaler@, P=O*OO5 for the MD1 plus 
spacer). 
All patients had previously used an inhaler 
device of some kind. Twenty-three of 24 patients 
for whom this information was recorded had 
used an MD1 previously. Fifty-eight per cent of 
these patients were able to use the Spacehaler@ 
as per written instructions at the first attempt. 
The corresponding figure for the MD1 plus 
spacer was 66%. The rest needed additional 
tuition once for both devices. There was no 
significant difference between the two devices as 
regards the ease of use. 
The relative preferences and opinions of 
the patients with regard to the two devices, 
as expressed in the completed patient 
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TABLE 1. Numbers and percentages of patients expressing preferences for the Spacehaler@ or the standard 
metered-dose inhaler (MDI) plus Volumatic@ spacer device in response to questions on the patient questionnaire 
Number (s) of patients 
Spacehaler@ MD1 + spacer Neither device Both devices equal 
Preferred device 
More convenient to use 
More comfortable to use 
Easier to co-ordinate 
(patient perception)* 
More portable 
20 (83.3) 3 (12.5) 1 (4.7) 0 
20 (83.3) 2 (8.3) 2 (8.3) 0 
18 (81.8) 1 (4.6) 3 (13.6) 0 
16 (73.9)* 1 (4.6)* 3 (13.6)* 2 (9.1)* 
20 (83.3) 2 (8.3) 2 (8.3) 0 
*For the purposes of this study, patients were required to demonstrate the ability to co-ordinate inspiration with 
dose release for both devices. 
questionnaires, are shown in Table 1. 
The Spacehaler@ was the preferred device, and 
the majority of patients thought it was more 
convenient and comfortable to use, easier to 
co-ordinate and more portable than the MD1 
plus spacer device. When asked if they would be 
happy if prescribed the Spacehaler@, 21 of 24 
patients (87.5%) said ‘yes’. 
Discussion 
This study shows that the bronchodilator effect 
achieved by 200,~g of salbutamol using the 
Spacehale? is identical to that achieved using a 
standard MD1 with a Volumatic@ spacer. The 
confidence limits for the difference show that one 
can be 99% certain that the difference in the 
weighted mean FEV, between the two devices is 
no more than 0.071 1. Analyses of other variables 
also showed no difference between the devices. 
These findings confirm and extend the obser- 
vations of two previous studies with a low- 
velocity pressurized aerosol inhaler. Newman 
and Clarke (8) found that the FEV,, FVC, PEF 
and maximum mid-expiratory flow rate showed 
similar increases with 100,ug of salbutamol 
delivered by a Gentlehale@) and a MD1 used 
correctly. Chipps et al. (7) also found no differ- 
ence in various lung functions after admin- 
istration of three puffs of Proventil@ (equivalent 
to 3OOpg of salbutamol) either by a 
Gentlehaler@ or an MD1 used with an 
Aerochamber@. Further studies are required to 
determine whether the Spacehaler@ and MD1 
plus a large volume spacer are equally effective 
in achieving bronchodilation at lower dose levels 
of salbutamol, although the lowest available 
dose is 50,~g. Since the dose response for sal- 
butamol tends to be flat above 20O,~~g, it is 
unlikely that higher dose studies would provide 
any useful information. Future studies to 
develop non-chlorofluorocarbon (hydrofluoro- 
alkane) formulations will also be required. 
Data recorded on device handling showed that 
around 60% of patients were able to use both 
inhalation devices correctly after reading the 
instruction leaflet. The rest of the patients 
needed additional tuition only once for both 
devices. There was no significant difference in the 
abilities of the patients to learn to use either 
device. At the end of the study, the majority of 
patients (more than 80%) preferred the 
Spacehaler@, and most patients found it to be 
more portable, easier to co-ordinate, and more 
comfortable and convenient to use than the 
MD1 plus spacer device. Only three patients 
preferred the Volumatic@ Spacer plus MDI. 
Two of these were over 50 years of age, while 10 
of the 20 patients who preferred the 
Spacehaler@ were over 50 years of age. There 
was, therefore, no age-related bias in patient 
preference. In the study by Chipps et al. (7), the 
majority of patients (22 of 30, 73%) also pre- 
ferred the Gentlehaler@ to the standard MD1 
plus Aerochamber @. The Spacehaler@ may, 
therefore, be a useful alternative to the standard 
316 K. A. GUNAWARDENA ET AL. 
MD1 plus spacer in appropriate patients, 
especially in cases where a reduction in oro- 
pharyngeal deposition and/or ‘cold-Freon effect’ 
is required. 
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